Agios Pharmaceuticals (NASDAQ:AGIO) had its target price hoisted by stock analysts at Cantor Fitzgerald from $70.00 to $72.00 in a report released on Friday, AnalystRatings.com reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 58.87% from the company’s current price.
Other analysts have also recently issued reports about the company. Guggenheim boosted their price objective on Agios Pharmaceuticals from $60.00 to $66.00 and gave the company a “buy” rating in a research report on Monday, June 15th. SVB Leerink increased their price objective on shares of Agios Pharmaceuticals from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Monday, June 15th. Citigroup lifted their target price on shares of Agios Pharmaceuticals from $64.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, June 15th. Piper Sandler increased their price target on shares of Agios Pharmaceuticals from $70.00 to $80.00 and gave the stock an “overweight” rating in a research report on Friday, June 12th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $72.00 price objective on shares of Agios Pharmaceuticals in a report on Friday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $68.77.
Shares of Agios Pharmaceuticals stock opened at $45.32 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.41 and a quick ratio of 8.27. The firm has a fifty day moving average price of $51.61 and a two-hundred day moving average price of $47.27. Agios Pharmaceuticals has a fifty-two week low of $27.77 and a fifty-two week high of $56.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.36) by $0.05. Agios Pharmaceuticals had a negative net margin of 182.49% and a negative return on equity of 59.38%. The business had revenue of $37.30 million during the quarter, compared to analysts’ expectations of $37.17 million. During the same quarter last year, the company earned ($1.87) earnings per share. The firm’s revenue was up 42.4% on a year-over-year basis. As a group, analysts expect that Agios Pharmaceuticals will post -4.67 EPS for the current fiscal year.
In other Agios Pharmaceuticals news, insider Christopher Bowden sold 3,583 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $50.01, for a total transaction of $179,185.83. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 3.16% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. M&T Bank Corp acquired a new stake in shares of Agios Pharmaceuticals in the 1st quarter valued at $10,644,000. Pearl River Capital LLC bought a new stake in Agios Pharmaceuticals during the 1st quarter worth about $32,000. Advisor Group Inc. raised its holdings in Agios Pharmaceuticals by 551.3% during the 4th quarter. Advisor Group Inc. now owns 1,244 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 1,053 shares during the last quarter. Carroll Financial Associates Inc. acquired a new position in Agios Pharmaceuticals during the 1st quarter valued at about $48,000. Finally, Parallel Advisors LLC boosted its stake in shares of Agios Pharmaceuticals by 1,510.3% in the 2nd quarter. Parallel Advisors LLC now owns 1,562 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 1,465 shares during the last quarter. Hedge funds and other institutional investors own 97.73% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Featured Story: What are catch-up contributions?
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.